Why semaglutide advertising is restricted — and what that means for you

What UK medicines law says about advertising prescription treatments

The prohibition on advertising prescription medicines to the public is not a technicality tucked away in guidance, it sits in Part 14 of the Human Medicines Regulations 2012 and carries real enforcement weight. A prescription-only medicine can only be obtained after a clinical assessment by a qualified prescriber. Advertising it to consumers would, in effect, encourage people to seek a specific medicine before any professional has judged it appropriate for them. That's the harm the law is designed to prevent.

Semaglutide falls squarely into this category. Wegovy (the weight-management brand) holds a UK marketing authorisation as a POM, and the MHRA has repeatedly stressed that GLP-1 receptor agonists (including semaglutide) are not suitable for everyone and carry a recognised side-effect profile that requires clinical oversight. You can read the patient-level detail on the NHS semaglutide medicines page. Anything that looks like a consumer advertisement for the medicine itself (urgency messaging, before-and-after claims, price-led promotion) is operating outside those rules. The line legitimate services walk is this: describing the clinical service is allowed; promoting the medicine as a product is not.

One concrete marker worth knowing: services that offer these medicines without mentioning a prescriber, a clinical assessment, or the prescription process are the ones that should give you pause.

How the MHRA applies advertising rules to semaglutide specifically

The MHRA has published specific public guidance on GLP-1 medicines, setting out what they are, who they are licensed for, and what responsible supply looks like. That guidance directly addresses the advertising space: claims that frame semaglutide as a shortcut, a cosmetic fix, or a guaranteed result misrepresent the medicine's licensed indication and its evidence base.

For context, the clinical trial evidence (the STEP 1 study, published in the New England Journal of Medicine) showed an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, in adults with obesity, alongside lifestyle changes. That is a meaningful result. It is also a result achieved in a supervised trial setting, over well over a year, with a specific population. Quoting it as a universal guarantee (or implying that results arrive faster) goes beyond what the evidence supports and beyond what the MHRA considers acceptable communication.

The regulator has also moved on enforcement. Suspect sellers and illegal promotions can be reported via the MHRA's Yellow Card scheme, which handles both adverse event reports and concerns about suspect products or promotional material. If you see a social-media post, an influencer partnership, or a website that reads more like a product advertisement than a clinical service, that is the right place to flag it.

What this means if you're researching semaglutide for weight management

Spend ten minutes searching and you will notice that some providers describe their process in careful, measured terms while others lean heavily on before-and-after language, time-limited offers, or celebrity framing. The careful ones are not being evasive, they are being compliant. The bold ones are worth scrutinising.

A GPhC-registered pharmacy prescribing semaglutide will describe what a consultation involves, who reviews your answers, and what clinical criteria matter. It will not promise a specific result or use promotional language around the medicine itself. That is the structure Wegovy treatment should sit within: a clinical service, not a retail transaction. If you want to understand the full treatment journey before you decide anything, how semaglutide is used in practice is a useful starting point.

On pricing specifically, legitimate providers discuss what their service includes (consultation, prescription, delivery, aftercare) rather than dropping per-pen prices as selling points. A broader look at how Wegovy pricing compares across UK providers explains what those costs typically cover and why variation exists. Cost is a reasonable thing to weigh up; the advertising rules exist partly to stop price becoming the dominant signal when safety should be.

How to recognise a compliant clinical service

The practical upshot of all of this is a short checklist any reader can apply. A compliant service will be verifiable on the GPhC pharmacy register, every registered online pharmacy has a premises registration number you can look up in seconds. It will describe a consultation process led by a qualified prescriber, not an automated questionnaire with an automatic approval. It will present a transparent price for the service, not a discount on the medicine. And it will include clinical aftercare, because semaglutide is a long-term treatment that requires ongoing review.

There is also what a compliant service will not do: it will not advertise semaglutide as universally safe, guarantee results, or suggest that clinical assessment is a formality. Our clinical team at nume takes the same approach to structuring a semaglutide treatment plan, the prescriber reviews your full picture, not just your BMI, before any decision is made. That review covers your health history, any other medicines you take, and whether the likely benefits outweigh the risks for you specifically. The advertising rules, in other words, are not a nuisance to work around; they map almost exactly onto good clinical practice.

If you have questions about side effects before committing to anything, the semaglutide side-effect profile is worth reading in full. When you're ready to find out whether treatment is appropriate for you, check your eligibility with our prescribers, no sales pitch, just a clinical assessment.